Related Experiment Video
Updated: Jul 19, 2026

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
[Experiences with Depo-Provera (medroxyprogesterone) in the treatment of kidney tumors]
Abstract:
30 patients with renal tumours were treated with Depo-Provera (Medroxyprogesterone). Among the 21 patients operated on without metastases and with an parallel metastasis (fibrous capsule, adipose capsule, peritoneum) in the course of 6 to 15 months no one died of a tumour progression. Among the 9 patients with a distant metastasis in one case the regression of the metastasis could be achieved, whereas in another case progesterone stopped the progression of the intraoperatively observed liver metastasis.
Insights
Medroxyprogesterone acetate (Depo-Provera) showed promising results in renal tumor patients. No tumor progression deaths occurred in patients without distant metastases, and some distant metastases showed regression or halted progression.
Area of Science:
- Oncology
- Pharmacology
Context:
- Renal tumors represent a significant clinical challenge.
- Medroxyprogesterone acetate (Depo-Provera) is a progestin with potential anti-cancer properties.
Purpose:
- To evaluate the efficacy of Medroxyprogesterone acetate in patients with renal tumors.
Summary:
- Thirty patients with renal tumors received Medroxyprogesterone acetate treatment.
- In 21 patients without distant metastases, no tumor progression was observed within 6-15 months post-surgery.
- Among 9 patients with distant metastases, one experienced regression, and another showed halted progression of liver metastases.
Impact:
- Medroxyprogesterone acetate may offer a therapeutic option for managing renal tumors, particularly in preventing progression.
- Further research is warranted to explore its role in advanced renal cell carcinoma.
More Related Videos
Related Concept Videos
Renal Drug Excretion: Tubular Reabsorption
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management

